Sector News

AbbVie announces executive leadership changes

December 19, 2018
Life sciences

AbbVie, a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its long-term growth strategy. Effective immediately, the new Team will consist of the following individuals, all of whom report to AbbVie Chairman and Chief Executive Officer Richard A. Gonzalez:

  • Michael E. Severino, M.D., AbbVie’s Executive Vice President, Research & Development and Chief Scientific Officer, has been named Vice Chairman and President. In his role, Dr. Severino will be responsible for research and development, human resources, operations, and the corporate strategy office.
  • Laura J. Schumacher has been named Vice Chairman, External Affairs and Chief Legal Officer. Ms. Schumacher currently serves as Executive Vice President, External Affairs, General Counsel and Corporate Secretary. In her new role, Ms. Schumacher will be responsible for legal, ethics and compliance, corporate governance, corporate aviation and all externally facing functions including health economics outcomes research, government affairs, corporate responsibility, brand and communications.
  • Carlos Alban, who currently serves as Executive Vice President, Commercial Operations, has been named Vice Chairman, Chief Commercial Officer. Mr. Alban will be responsible for global commercial operations of the Company, including the addition of Pharmacyclics commercial functions.
  • William J. Chase will continue in his role as Executive Vice President, Finance and Administration, responsible for all financial and administrative functions of the Company.

“AbbVie has grown significantly since our founding six years ago, and now is the right time to evolve our senior executive leadership structure to match our talent and our operating model as well as support our long-term growth strategy,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “We are fortunate to have a deep pool of senior leadership talent, and this streamlined structure will enhance our ability to execute against our long-term strategies, provide additional scope for our senior leaders and facilitate our ability to meet our commitment to continuing to deliver value to all of our stakeholders, including patients, employees, shareholders and the communities we serve.”

Source: AbbVie via PharmaLive

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend